1000 Participants Needed

Genomic Predictors for Miscarriage

(GPRPL Trial)

Recruiting at 10 trial locations
YJ
HZ
Overseen ByHeping Zhang, PhD
Age: 18 - 65
Sex: Any
Trial Phase: Academic
Sponsor: Yale University
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to understand the genetic factors that might lead to recurrent pregnancy loss (RPL). Researchers seek to identify specific genes or DNA patterns that could help predict the likelihood of experiencing RPL. Women who have lost a pregnancy before 20 weeks and have had at least one other pregnancy loss might be suitable for this study. The goal is to discover new ways to prevent RPL by studying the genetics of those affected.

As an unphased study, this trial offers participants the chance to contribute to groundbreaking research that could lead to future prevention strategies for RPL.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Why are researchers excited about this trial?

Researchers are excited about this trial because it aims to uncover the genomic predictors of recurrent pregnancy loss, a condition with limited understanding and treatment options. Unlike current approaches that mainly address lifestyle factors or hormonal treatments, this research dives into the genetics behind the condition, potentially offering new insights into causes and personalized prevention strategies. By identifying specific genetic markers, this study could pave the way for targeted therapies and improved outcomes for those experiencing recurrent pregnancy loss.

Are You a Good Fit for This Trial?

Inclusion Criteria

You have a diagnosed date for your condition.
Ultrasound results indicate your gestational age at the time of diagnosis.
You have a documented maternal result and date.
See 16 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Sample Collection

Collection of DNA samples from trios (POC, biological mother, and biological father) and potentially other family members

Ongoing

Whole Genome Sequencing

Whole genome sequencing and bioinformatic analyses to identify pathogenic variants

5 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • None

Find a Clinic Near You

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials
1,963
Recruited
3,046,000+

The University of Texas Health Science Center at San Antonio

Collaborator

Trials
486
Recruited
92,500+

Wayne State University

Collaborator

Trials
318
Recruited
111,000+

University of Oklahoma

Collaborator

Trials
484
Recruited
95,900+

Columbia University

Collaborator

Trials
1,529
Recruited
2,832,000+

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Collaborator

Trials
2,103
Recruited
2,760,000+

Northwestern University

Collaborator

Trials
1,674
Recruited
989,000+

University of Chicago

Collaborator

Trials
1,086
Recruited
844,000+

University of Colorado, Denver

Collaborator

Trials
1,842
Recruited
3,028,000+

Augusta University

Collaborator

Trials
219
Recruited
85,900+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security